{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2023:BVFLGAODE2YAS2JUOMUURAXYUR","short_pith_number":"pith:BVFLGAOD","schema_version":"1.0","canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","source":{"kind":"arxiv","id":"2304.03476","version":2},"attestation_state":"computed","paper":{"title":"Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Bo Zhang, Fei Gao, Oliver Dukes, Qijia He, Sinead Delany-Moretlwe","submitted_at":"2023-04-07T04:48:33Z","abstract_excerpt":"In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) in a population of heterosexual women in 7 African countries. One key complication of interp"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2304.03476","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","cross_cats_sorted":[],"title_canon_sha256":"da4a35e1d381f60c76a092805418c2b04a3a20699476421e23fb3d4a3a8c0589","abstract_canon_sha256":"b600cbdd0298e3a2ec628c5602f237ecbc04ec1795727d1dce7c51e49c63ec61"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T07:28:44.049118Z","signature_b64":"T6knU3FgSlmwFU7Z0W0vTBBurOQK110l0hlGoG2FPIwCl7IFQV5UeqVwPcX/+yLTDGELYiQYDDO7lFB/+R4nDA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","last_reissued_at":"2026-07-05T07:28:44.048654Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T07:28:44.048654Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Bo Zhang, Fei Gao, Oliver Dukes, Qijia He, Sinead Delany-Moretlwe","submitted_at":"2023-04-07T04:48:33Z","abstract_excerpt":"In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) in a population of heterosexual women in 7 African countries. One key complication of interp"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2304.03476","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2304.03476/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2304.03476","created_at":"2026-07-05T07:28:44.048714+00:00"},{"alias_kind":"arxiv_version","alias_value":"2304.03476v2","created_at":"2026-07-05T07:28:44.048714+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2304.03476","created_at":"2026-07-05T07:28:44.048714+00:00"},{"alias_kind":"pith_short_12","alias_value":"BVFLGAODE2YA","created_at":"2026-07-05T07:28:44.048714+00:00"},{"alias_kind":"pith_short_16","alias_value":"BVFLGAODE2YAS2JU","created_at":"2026-07-05T07:28:44.048714+00:00"},{"alias_kind":"pith_short_8","alias_value":"BVFLGAOD","created_at":"2026-07-05T07:28:44.048714+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":1,"internal_anchor_count":1,"sample":[{"citing_arxiv_id":"2505.11444","citing_title":"A Generative Framework for Causal Estimation via Importance-Weighted Diffusion Distillation","ref_index":9,"is_internal_anchor":true}]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR","json":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR.json","graph_json":"https://pith.science/api/pith-number/BVFLGAODE2YAS2JUOMUURAXYUR/graph.json","events_json":"https://pith.science/api/pith-number/BVFLGAODE2YAS2JUOMUURAXYUR/events.json","paper":"https://pith.science/paper/BVFLGAOD"},"agent_actions":{"view_html":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR","download_json":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR.json","view_paper":"https://pith.science/paper/BVFLGAOD","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2304.03476&json=true","fetch_graph":"https://pith.science/api/pith-number/BVFLGAODE2YAS2JUOMUURAXYUR/graph.json","fetch_events":"https://pith.science/api/pith-number/BVFLGAODE2YAS2JUOMUURAXYUR/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/action/timestamp_anchor","attest_storage":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/action/storage_attestation","attest_author":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/action/author_attestation","sign_citation":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/action/citation_signature","submit_replication":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/action/replication_record"}},"created_at":"2026-07-05T07:28:44.048714+00:00","updated_at":"2026-07-05T07:28:44.048714+00:00"}